ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation

R. L. Talbert, R. G. Hart

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Stroke is a catastrophic, but largely preventable, consequence of AF. ASHP supports recommendations established by the American College of Chest Physicians (Table 1) for the use of antithrombotic therapy in appropriate patients to reduce the morbidity and mortality associated with stroke. The selection of warfarin versus aspirin should be based on the presence of clinical risk factors for stroke and the patient's ability to safely undergo anticoagulation therapy. Adequate patient education and monitoring are keys to the successful use of antithrombotic therapy, and ASHP believes that pharmacists can play an important role in providing these services.

Original languageEnglish (US)
Pages (from-to)376-381
Number of pages6
JournalAmerican Journal of Health-System Pharmacy
Issue number4
StatePublished - Feb 15 1998


  • American Society of Health-System Pharmacists
  • Anticoagulants
  • Aspirin
  • Atrial fibrillation
  • Cerebrovascular disorders
  • Organizations
  • Patient education
  • Pharmacists
  • Platelet aggregation inhibitors
  • Protocols
  • Warfarin

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy


Dive into the research topics of 'ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation'. Together they form a unique fingerprint.

Cite this